Opinion on Medical Devices and Diagnostics

Published within

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

Type Product title / description Pub Price
Expert View
Expert View

APA 2010: unmet needs in major depressive disorder remain key

Key themes presented in the field of major depressive disorder at this year's American Psychiatric Association annual meeting included treatment-resistant depression, transcranial magnetic stimulation and adjunctive use of antipsychotics. While no new clinical trial data were presented, those that were provide an interesting insight into the strategies of a number of major pharmaceutical players.

Published By Datamonitor
10 Jun 2010
Expert View
Expert View

ATS 2010: developments in IPF and cystic fibrosis

The FDA's recent refusal of Esbriet and the publication of new guidelines for the treatment of idiopathic pulmonary fibrosis drove considerable interest in this disease at the 2010 meeting of the American Thoracic Society. Furthermore, the approval of the first new inhaled antibiotic for cystic fibrosis in over a decade brought renewed focus on this rare but extremely debilitating disease.

Published By Datamonitor
04 Jun 2010
Expert View
Expert View

ATS 2010: shift in asthma guidelines highlights focus on personalized medicine

Datamonitor attended this year's meeting of the American Thoracic Society in New Orleans. The 2010 conference was defined not only by the latest clinical trial data, but by new guidelines and an emerging discussion of the role of personalized treatment. Conclusions were also presented from the ISAAC study, highlighting some surprising global prevalence trends.

Published By Datamonitor
04 Jun 2010
CommentWire
CommentWire

ChemGenex: leukemia drug setback proves importance of diagnostics

Despite evidence of Omapro's efficacy in chronic myeloid leukemia patients, the FDA's oncology advisory committee has voted that a mutation assay should be reviewed before the regulator approves the drug. This underlines the importance of developing validated diagnostics to ensure consistent patient selection in the era of personalized medicine.

Published By Datamonitor
24 Mar 2010
Expert View
Expert View

AstraZeneca and Boehringer Ingelheim steal limelight at European Society of Cardiology meeting

Well crafted, positive results for AstraZeneca's Brilinta and an unexpected coup for Boehringer Ingelheim's Pradaxa dominated the headlines following this year's European Society of Cardiology's Annual Meeting in Barcelona. Both announcements have a number of important implications for the wider cardiology market, from both therapeutic and commercial perspectives.

Published By Datamonitor
03 Sep 2009
Expert View
Expert View

Intel's health guide puts telehealth in the spotlight

Intel has entered the healthcare market in full force with the announcement of its Intel Health Guide product. However, a closer look at the 'personal health system' reveals it to be something of a disappointment. Although Intel's entrance into the telehealth space will bring much needed attention to the emerging technology, the company's success in this competitive new arena remains to be seen.

Published By Datamonitor
13 Nov 2008
Expert View
Expert View

Can technology diminish reliance on heart transplants?

Growing risk factors in an ageing population have driven the rising prevalence of heart failure. With no new drug therapies, and existing pharmacological strategies failing to compensate for a weakening heart, other solutions must be found. Alternative technologies in particular have demonstrated promising results, suggesting we may soon eliminate the reliance on transplantation.

Published By Datamonitor
18 Jun 2008
CommentWire
CommentWire

Becton Dickinson: assay could improve MRSA treatment

The FDA has approved BD Diagnostics' StaphSR assay, which enables the rapid detection of Staphylococcus aureus and MRSA. Since the assay distinguishes between resistant and susceptible strains, its use will enable the faster administration of effective therapy, thereby preventing the spread of resistance and helping hospitals to reduce costs.

Published By Datamonitor
03 Jan 2008
CommentWire
CommentWire

Bristol-Myers Squibb: makes move to cut costs

Bristol-Myers Squibb has agreed to the sale of its medical imaging unit to a leading private equity firm in a $525 million transaction, two weeks after announcing plans to reduce its workforce by 10%, to concentrate resources on strengthening R&D productivity. BMS faces several key patent expiries at the end of the decade, and will rely on new launches to offset losses from its older products.

Published By Datamonitor
19 Dec 2007
CommentWire
CommentWire

Orthovita: Cortoss could generate high sales in the spinal fracture market

Orthovita is currently developing Cortoss as a treatment for vertebral compression fractures. Although the biomaterials company does not have as much experience in the spinal market as the bigger players such as Stryker and Medtronic, Cortoss is well-positioned to offer physicians distinct benefits over the current treatments, and Datamonitor expects peak sales for the therapy of $126m in 2013.

Published By Datamonitor
26 Oct 2007

« | 1 | 2 | 3 | 4 | 5 | 6 | 7 | 8 | » »|

No help is available.